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ABSTRACT 
Objective: The purpose of this study was to develop and evaluate methotrexate-loaded nanoemulgel for topical delivery in the management of 
rheumatoid arthritis. 
Methods: Based on nanoemulsion composition, the pseudo ternary phase diagram was fabricated by using peanut oil, Tween 20 as the surfactant, 
and PEG 400 being used as a co-surfactant. The methotrexate-loaded nanoemulsion was formulated by using the spontaneous emulsification 
method. Badam gum was used as a gel matrix in the prepared nanoemulsion to form nanoemulgel. The methotrexate-loaded nanoemulgel was 
characterized and evaluated for pH, particle size, physical appearance, viscosity, spreadability, TEM, drug content, diffusion study, release kinetics, 
and stability studies. 
Results: The nanoemulgel constituting 8.6% peanut oil, 34.4% of Tween 20 and PEG 400 as Smix (surfactant and co-surfactant mixture), 43% water, 
and 12.5% w/w badam gum was concluded as optimized formulation. The prepared nanoemulgel was translucent in nature having a particle size of 
195.1 nm and zeta potential of-0.278mV. Drug content and drug release for the optimized formulation were found to be 98.11±0.34% and 
95.11±0.02% respectively. pH, viscosity, and spreadability were found to be optimum. Stability study data showed that the prepared nanoemulgel 
was stable at different temperatures varying from-25 to+45 °C. 
Conclusion: Methotrexate-loaded nanoemulgel has been successfully formulated for topical drug delivery for the management of rheumatoid arthritis. 
Keywords: Methotrexate, Nanoemulgel, Rheumatoid arthritis, Topical delivery, Peanut oil 
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INTRODUCTION 
Rheumatoid arthritis is one of the complex autoimmune disorders 
associated with chronic inflammatory pain, and swelling of joints, 
elbows, shoulders, ankles, and other organs of the body [1]. It is 
based on numerous interacting eco-physiological and genetic factors 
that make it difficult to learn its pathogenesis and to detect effective 
treatment. In rheumatoid arthritis disease, the immune system of 
the body affects its tissues along with joints[2]. In extreme cases, the 
disease also affects the internal organs of the body [3]. The linings of 
joints are affected by Rheumatoid arthritis, which causes painful 
swelling. The long-term inflammation that is related to rheumatoid 
arthritis may cause erosion of bone and joint deformity. The focal 
point in the treatment of rheumatoid arthritis is pain reduction, 
reduction of inflammation, and damage to joints [4-6]. 
There are different routes of drug administration for the treatment 
of rheumatoid arthritis such as enteral routes such as oral, buccal, 
sublingual, and parenteral routes such as intramuscular, 
intravascular, subcutaneous, and intra-articular, or topical route[4]. 
In the topical drug delivery system, the drug is introduced onto the 
surface of the body, by incorporating it into a formulation that can 
be absorbed. Topical delivery provides several benefits over oral 
delivery for the treatment of diseases together with allowing easy 
and continuous delivery of drugs and minimizing the increased drug 
plasma concentration (Cmax) [7, 9]. 
However, the drug quantity introduced by dermal application is 
pretty less because the delivery of drugs through the dermal 
application is seriously restricted by the incapacity of various drugs 
to pass through the skin at a therapeutic rate because of the 
presence of the external stratum corneum membrane barrier. It has 
been predicted that the system which use nanoparticles to deliver 
drug may offer a different possible approach for influencing the 
permeability of drug and it is also feasible that a topical delivery 
system by using nanoparticles might also cause a selection of their 
utilization in the treatment of rheumatoid arthritis [8, 9]. 
The topical delivery systems of drugs involve different types of 
dosage forms such as liquid, sprays, semisolid and solid powders. 
The semisolid dosage form, which is most extensively used for 
topical delivery systems involves creams, ointments, and gels. The 
gel is a network of cross-linked polymer that is swollen when comes 
in contact with liquid. The properties of gel rely mostly on the 
interaction that occurs between the polymer of solid-state and the 
component of the liquid medium. The formulation of topical gel 
offers a suitable delivery system for drugs as they cause a low level 
of greasiness and might be eliminated from the skin without any 
difficulty. In comparison to cream and ointments, the gel 
preparation offers higher stability and application properties [8]. 
Nanoemulsions are heterogeneous colloidal systems in the submicronic 
scale whereas colloidal particulate structure is taken into consideration 
as isotropous dispersions which are thermodynamically and kinetically 
stable that includes two incompatible components viz., water and oil, 
stabilized by an associate surface layer that includes an acceptable co-
surfactant and surface active agent to create a single-stage [9]. The 
nanoemulsions have recently been categorized into three classes 
including oil-in-water kind (oil dispersed in water phase), (W/O) 
(aqueous phase is dispersed in oil phase), and bi-continuous type 
(microdomains of aqueous phase and oil phase are interconnected in the 
device). To stabilize these emulsions, both lipophilic and hydrophilic 
surface-active agents are concurrently used [10]. The nanoemulgel is a 
nanoemulsion-based hydrogel that is formed by adding nanoemulsion 
into a matrix of a hydrogel [13, 14]. Nanoemulgel has various useful 
properties such as easily spreadable, easy to remove, less greasy, cause 
no staining, longer shelf life, thixotropic, aqueous soluble, bio-friendly, 
acceptable appearance, and translucent [15-17]. 
MATERIALS AND METHODS 
Materials 
Methotrexate was procured from Samarth Life Sciences Pvt. Ltd., 
Mumbai, India; Peanut oil was procured from fresh mill oil, local 
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market; Tween 20 was purchased from Loba Chemie Pvt Ltd, 
Mumbai; Polyethylene Glycol 400 was purchased from Leonid 
Chemicals Pvt Ltd, Bangalore; Benzyl alcohol was purchased from 
Merck; Badam gum was prepared in the laboratory. Additional 
excipients and chemical reagents utilized were of laboratory and 
analytical grade. 
UV visible spectrophotometer 
A weighed amount of methotrexate nearly 100 mg was dissolved in 
100 ml of phosphate buffer of pH(6.8) in a volumetric flask and 
filtered. Pipette out 1 ml and make it up to 100 ml with the 
phosphate buffer. Then the λmax of methotrexate was estimated with 
the help of a UV visible spectrophotometer. 
Fourier transform infrared (FT-IR) analysis 
The drug-excipient compatibility of the pure drug and the physical 
mixture was determined using the FT-IR spectrophotometer (8400S, 
Shimadzu Kyoto, Japan). The pure drug methotrexate and the physical 
mixture were mixed separately with KBr in mortar and pestle and 
pressed in KBr press (Technosearch Instrument, Mumbai, India) at the 
pressure of 5 tons for 5 min to form KBr pellets or thin films and FT-IR 
spectra recorded in the wavelength range 4000-400 cm-1 [14]. 
Selection of excipients 
The emulgel preparation for topical application should be non-irritant 
and least sensitive to the skin. To maintain the solubility of the drug in 
nanoemulsion, the drug must be soluble in the oil phase. The stability 
of nanoemulsion is maintained by using higher and lower HLB value of 
surfactant and co-surfactant were considered [15]. 
Screening of oils, surfactants, and co-surfactants 
A primary examination of numerous oils, surface-active agents, and 
co-surfactants has been completed to check their lodging capacity 
toward methotrexate. The miscibility of Methotrexate in numerous 
oils, surface-active agents, and co-surfactants has been identified by 
adding an extra quantity of drug into 2 ml of decided oil, surface 
active agent, and co-surfactant one after the other in a separate 10 
ml volumetric flask via the use of a vortexing mixer. These 
volumetric flasks had been stored in an orbital shaker incubator 
(Remi, CIS24 BL, Mumbai, India) at 25±1.0°C for 72 h to attain a 
state of equilibrium. The samples which were equilibrated have 
been taken out from the shaker and centrifugation was done at 3000 
RPM over 15 min by the use of centrifuge (Remi, India). Then, the 
supernatant formed has been taken and performed filtration of 
supernatant by using a filter paper. The methotrexate concentration 
has been identified in specific oil using UV-spectroscopy at 259 nm 
[19, 20]. 
Construction of pseudo-ternary phase diagram 
The pseudo ternary phase diagrams had been constructed by using 
the method of aqueous titration to determine the region of 
nanoemulsion and to identify the size of the nanoemulsion region. 
For the construction of each pseudo-ternary phase diagram, the 
surfactant was mixed with co-surfactant (Smix) in the ratio of 1:1, 1:2, 
1:3, 3:1, and 2:1 (i.e., Km, w/w). Then the part of each Smixhas been 
combined with the oil in the ratio of 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 
2:8, and 1:9 (w/w). By vortexing with vortexer for 5 min, a 
transparent homogenous mixture of oil and the Smix component had 
been prepared [18]. Then titration of each mixture was carried out 
in drop by drop method with distilled water and prominently 
viewed for clarity of phase and ability to flow. The volume of water 
at which the transitions from transparency to turbidity occurred 
was supposed to be the titration’s endpoint. From this titration 
method, the ratio of surfactant/co-surfactant (Smix) has been 
determined. These estimated values were utilized to identify the 
region of the nanoemulsion formulation with the selected amount of 
oil and surfactant and co-surfactant (Smix). Then the drug effect on 
the boundary of nanoemulsion that has been obtained from the 
pseudo ternary phase diagram was checked. The pseudo ternary 
phase diagram was constructed using the ProSim Ternary Diagram 
software [21, 22]. 
Preparation of methotrexate loaded nanoemulgel 
Formulation of methotrexate nanoemulsion 
Methotrexate (1%) was added to the mixture of tween 20, PEG 400, 
and peanut oil ratios (table 1) taken from the pseudo ternary phase 
diagram. The water was then added dropwise to the above solution 
and stirred at room temperature [21]. 
Formulation of methotrexate nanoemulgel 
A measured amount of badam gum was added to distilled water and 
mixed it properly using a magnetic stirrer. The stirring was carried 
out uniformly and the gel was placed in the refrigerator for 24 h. The 
formulation (F1-F3) was prepared using S3 nanoemulsion 
containing a Smix ratio of 3:1 given in table 2 [5]. 
 
Table 1: Composition of nanoemulsion with selected oil, surfactant, and co-surfactant 
Nanoemulsion code Smix* Excipients (%w/w) 
Peanut oil Tween20:PEG400 (Smix) Water 
S1 1:1 15 45 40 
S2 2:1 10 45 45 
S3 3:1 10 40 50 
Note: Smix represents the ratio of surfactant to cosurfactant. 
 
Table 2: Composition of 0.5% w/w methotrexate-loaded nanoemulgel 
S. No. Materials F1* F2* F3* 
1 Methotrexate 0.5 0.5 0.5 
2 Peanut Oil 12.9 8.6 8.6 
3 Tween 20:PEG400 (Smix) 38.7 38.7 34.4 
5 Water 34.4 38.7 43 
6 Badam Gum (1.5%) 12.5 12.5 12.5 
7 Benzyl Alcohol 1.5 1.5 1.5 
Note: F1, F2, and F3 represent the formulations of Methotrexate-loaded nanoemulgel. 
 
Evaluation of nanoemulgel 
Transmission electron microscope 
The size and shape of nanoemulgel were examined by transmission 
electron microscope (TEM) (Philips CM 10, Philips electron optics, 
Eindhoven, The Netherlands) with the image software. The drug-
loaded emulsion was spread on firmware-coated copper grids and 
absorbed after complete air drying [24, 25]. 
Particle size analysis 
The particle size of the formulated nanoemulgel was measured using 
the dynamic light scattering method or photon correlation 
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spectroscopy by using Zeta sizer (ZS 90, Malvern Instrument Ltd, 
UK). The prepared nanoemugel was diluted with deionized water 
(1:1000) and measured for the particle size [26, 27]. 
Measurement of zeta potential 
Zeta potential for nanoemulgel was estimated using Zeta sizer (ZS 
90, Malvern Instrument Inc, UK) by using an electrophoretic light 
scattering method. The formulated sample was placed in zeta cells 
and results were analyzed. The average of three measurements with 
Standard Deviation (±SD) was reported [26, 28]. 
Evaluation of nanoemulgel 
Physical appearance of nanoemulgel 
The formulated nanoemulgel was examined visually for color, pH, 
homogeneity, stability, and consistency [27]. 
Determination of pH  
The pH of the formulated nanoemulgel was identified by utilizing a 
digital pH meter. By using distilled water the electrode of the pH 
meter has been washed and then the electrode was dipped inside 
the formulation to estimate pH [28]. 
Viscosity measurement  
The viscosity of nanoemulgel was measured by Brookfield Viscometer 
(Brook field DV II+, USA), with spindle no. 63 at 30-50 RPM [25]. 
Spreadability study 
Spreadability was estimated by calculating the diameter of the spreading 
of 1g of formulation between two glass plates and for one minute when a 




where, S = spreadability (cm. g/sec), M=weight of the upper slide 
(g), L=length of the glass slide (cm)and T=time taken for separation 
of slide (sec) [29]. 
Drug content study  
The study of drug content has been performed to estimate the 
presence of the drug in a certain amount of the prepared formulation. 
0.1g of the nanoemulgel has been weighed accurately and dissolved in 
25 ml of phosphate buffer (pH 6.8). Then the volumetric flask was 
placed in an orbital shaker and shaken well to mix it properly. The 
solution was then filtered, suitably diluted and the absorbance was 
determined by UV-spectrophotometer at 259 nm [16]. 
Drug release studies 
The release rate of methotrexate from nanoemulgel was performed 
using Franz diffusion cell (Perme Gear, Bethlehem, PA, USA), with a 
dialysis membrane of 0.65 µm pore size. The diffusion test apparatus 
was performed using 900 ml of phosphate buffer of pH 6.8 at 
37°C±1°C and 50 RPM for 12 h. The methotrexate-loaded nanoemulgel 
was employed on the surface of the membrane in the donor chamber. 
Then the sample (5 ml) was collected at a suitable interval of time (1, 
2, 3, 6, 9, and 12hr) from the receptor chamber, and to maintain the 
sink condition the receptor chamber was restored with buffer media. 
Then the collected samples were assayed for the measurement of drug 
content by utilizing a UV-visible spectrophotometer (UV-1800, 
Shimadzu, Kyoto, Japan) at λmax of 259 nm [30]. 
Release kinetics 
The cumulative drug release data was used to obtain mathematical 
models (Zero-order release, First-order release, Higuchi, and 
Korsmeyer-Peppas model) using BCP software [27]. 
Accelerated stability studies 
The stability of the prepared nanoemulgel formulation was 
estimated using the heating-cooling cycle method and free thaw 
cycle method [31]. 
Heating cooling cycle method 
In this method, 6 cycles were carried out between the refrigerator 
temperature (4°C and 45°C) with the storage of the sample at each 
temperature for at least 48 h [16]. 
Free thaw cycle 
In this method, the prepared nanoemulgel was initially placed in a 
deep freezer at a temperature of-25°C, then formulation was 
removed and allowed for thawing at a temperature of 25°C (room 
temperature). The formulation was then observed for appearance, 
pH, and a viscosity [23]. 
RESULTS AND DISCUSSION 
Pre-formulation studies 
The absorption maxima of methotrexate were estimated at 259 nm 
in phosphate buffer of pH 6.8. 
Fourier transform infrared spectroscopy (FT-IR) 
The FT-IR spectrum of pure methotrexate was compared with the 
FT-IR spectra of drug and excipients as shown in fig. 1. The 
functional group along with their wavenumbers obtained for both 
the pure drug and the physical mixture has been listed in table 3. 
The characteristic IR peaks of pure Methotrexate were found to be at 
1446.66 (C-H bending, deformation of CH3), 1637.48 (C=C 
stretching), 2928.04 (C-H stretching, aliphatic), 3371.63 (O-H 
stretching) [32]. All these peaks were found to be in the IR spectra of 
the physical mixture with not so much major shifting. Therefore, 
both pure drug and the physical mixture were in correlation with all 
the characteristic IR spectra peaks and the results revealed no 
chemical interaction between drug and excipients. 
  
 
Fig. 1: FT-IR spectra of (A) methotrexate and (B) Physical mixture (Methotrexate+Peanutoil+Tween 20+PEG 400) 
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Table 3: FTIR spectrum of the pure drug (methotrexate) and the physical mixture 
Functional group Pure drug Physical mixture 
C=Cstretch 1637.48 1647.26 
C-H bend (deformation of CH3) 1446.66 1458.23 
C-H stretch (Aliphatic) 2928.04 2916.47 
O-H stretch 3371.63 3471.98 
 
Pseudo-ternary diagram 
From the pseudo-ternary-phase diagram, it has been observed that 
there is a slight alteration in the nanoemulsion region with the 
increase in the surfactant ratio. Hence, according to the pseudo-phase 
ternary diagram, the S3 formulation, a 3:1 ratio of Smix (Tween 20:PEG 
400) was considered. The 1:9 ratio of oil: Smix has been considered as 
the maximum region of nanoemulsion as depicted in fig. 2. 
 
 
Fig. 2: Pseudo-ternary phase diagram of methotrexate 
 
Evaluation of nanoemulsion 
Transmission electron microscope (TEM) 
TEM was implied for evaluating particle shape and size of 
nanoemulgel. The TEM results of optimized formulation F3 revealed 
that the particle size of methotrexate-loaded nanoemulgel was found 
to be 195.1 nm, the same when compared with the particle analyzer 
(fig. 3b), with the uniform shape of particles. The TEM images of 
nanoemulgel are depicted in fig. 3a. 
Particle size analysis 
The particle size of the formulation was found to be 195.1 nm and 
the polydispersity index (PDI) was found to be 0.326 as shown in fig. 
3b. As per the thumb rule, the PDI value was found to be 
monodisperse and ensures stability. 
 
Fig. 3a: TEM image of methotrexate loaded nanoemulgel
 
 
Fig. 3b: Particle size of methotrexate loaded nanoemulgel 
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Fig. 4: Zeta potential of methotrexate loaded nanoemulgel 
 
Measurement of zeta potential 
The zeta potential of the prepared formulation was–0.278 mV, which 
was within the limit, and indicates thermodynamic stability as 
shown in fig. 4. 
Evaluation of nanoemulgel 
Physical appearance of nanoemulgel 
The nanoemulgel prepared using badam gum was yellowish, 
translucent, and consistent in appearance. 
Determination of pH  
The pH of these formulations was ranged between 5.8 and 6.7. 
Which are considered acceptable and less irritable for use in human 
skin, as human skin pH is 5.5. Therefore, it is feasible to apply on the 
skin with no irritation. 
Viscosity measurement  
The viscosity of nanoemulgel was found to be 1533.1cps at 50 rpm, 
implying the better consistency of the dosage form. 
Spreadability study 
The spreadability of nanoemulgel was found to be 28.85 g cm/sec. 
Hence, the range was acceptable. 
Drug content study  
The drug content of a nanoemulgel was 98.11±0.34%, implying that 
a significant amount of the drug was loaded in the nanoemulgel. 
Drug release study 
In vitro drug release of the optimized formula was performed in PBS 
of pH 6.8 by using a dialysis membrane. The F3 formulation showed 
burst release initially as compared to the other formulations. The 
drug release of optimized drug-loaded nanoemulgel (F3) was found 
to be 95.11% in 12 h when compared to other formulations and is 
depicted in table 4 and fig. 5. 
Release kinetics 
The optimized drug-loaded nanoemulgel (F3) showed the highest 
percentage of drug release of 95.11% when compared to the other 
formulations and followed first-order kinetics. Therefore, the release 
profile that followed the diffusion process is the First Order model 
with an R2value of 0.9915and also achieved a linear relationship as 
given in table 5. 
Accelerated stability studies 
Under all storage conditions, the optimized formula has been kept and 
the physical characteristics have been evaluated. From the stability 
study, it has been found that the prepared nanoemulgel was physically 
stable at all storage conditions with no phase separation, caking, and 
creaming. Hence, the optimized formula is kinetically stable. 
 
Table 4: Data for in vitro drug diffusion studies 
Time in hours % Drug diffused (w/w) 𝐌𝐞𝐚𝐧 ± 𝐒𝐃* 
F1 F2 F3  
0 0.00 0.00 0.00 
1 4.09±0.03 5.12±0.02 7.02±0.05 
2 15.06±0.04 15.88±0.03 16.92±0.03 
3 22.55±0.05 23.78±0.02 26.63±0.05 
6 40.98±0.02 42.01±0.01 44.72±0.02 
9 59.12±0.03 58.67±0.04 61.26±0.01 
12 80.24±0.01 85.19±0.002 95.11±0.02 
NOTE: *Data represented as mean±SD (n=3) 
 
Table 5: Release kinetics at 259 nm 
Mathematical model R2 of nanoemulgel (F3) 
Zero Order Release 0.9894 
First Order Release 0.9915 
Higuchi Model 0.9168 
Korsmeyer Peppas Model 0.9881 
NOTE: R2=Regression coefficient value 
S. Das et al. 




Fig. 5: Graph showing percentage drug diffused of methotrexate and nanoemulgel at 259 nm 
 
CONCLUSION 
Topical drug delivery is the preferred route for the local application 
of the therapeutic drug because of its ease and affordability. It has 
also gained popularity in recent years among the population due to 
better patient compliance. Therefore, a potential methotrexate-
loadednanoemulgel using peanut oil as the oil phase and badam gum 
as a gelling agent was formulated successfully and characterized 
along with an in vitro study. The optimized formulation (F3) showed 
95.11% in 12 h which is more than the other formulation and also 
resulted in better physicochemical properties. The product exhibit a 
good stability profile at all storage condition mentioned in the 
methodology. So, from this research study, it has been found that 
methotrexate is a disease-modifying antirheumatic drug with a better 
retention time as compared to other drugs. Hence, the study 
demonstrated that the prepared nanoemulgel was found to be an 
operative tool in the management of rheumatoid arthritis when 
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